cancer-therapy-and-biomarkers-2016_tracks-abstracts

8 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 30
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
ERC/mesothelin as a biomarker for mesothelioma and gastrointestinal cancer
Tomoaki Ito
Juntendo Shizuoka Hospital-Juntendo, University School of Medicine, Japan
Previously, we found that the ERC (Expressed in Renal Carcinoma) gene was preferentially expressed in renal cancers in the
Eker rat. Furthermore, we subsequently confirmed that ERC is a homolog of the human mesothelin gene, a gene that is
strongly expressed in normal mesothelial cells, mesotheliomas, and non-mucinous ovarian carcinomas. The ERC/mesothelin
gene (MSLN) encodes a 71kDa precursor protein, which is cleaved to yield 31kDa N-terminal (N-ERC/mesothelin) and 40
kDa C-terminal (C-ERC/mesothelin) proteins. N-ERC/mesothelin (also known as megakaryocyte-potentiating factor; MPF)
is a soluble protein and is released into the extracellular space and blood. C-ERC/mesothelin is a glycoprotein that is tethered to
the cell surface by a glycosylphosphatidylinositol anchor. C-ERC/mesothelin expression of tumor by immunohistochemistry
can be correlated with patient’s survival in several human cancers. Soluble Mesothelin-Related Peptide (SMRP) has proven to
be a promising biomarker in the sera of patients with mesothelioma and ovarian cancer. As for secreted N-ERC/mesothelin,
we previously devised a novel Enzyme-Linked Immunosorbent Assay (ELISA) system for determining its concentration in
serum and showed that it is useful for diagnosing human mesothelioma and ovarian cancer. In addition, we demonstrated that
C-ERC/mesothelin was expressed in gastric cancer and pancreatic cancer tissues. Meanwhile, increased serum N-ERC/meso-
thelin concentrations are not specific to these patients with gastric cancer or pancreatic cancer. Although N-ERC/mesothelin
is established as a reliable marker for mesothelioma, N-ERC/mesothelin is not useful as a diagnostic marker of gastric cancer
and pancreatic cancer.
Biography
Tomoaki Ito received the MD in 2000 and the PhD in Medical Science from Juntendo University, Tokyo, Japan. He completed Post-doctoral studies from Stanford
University School of Medicine. He is an Assistant Professor of Department of Surgery, Juntendo Shizuoka Hospital, Juntendo University School of Medicine,
Shizuoka, Japan. His research interests include oncology and cancer biomarker.
Tomoaki Ito, Oncol Cancer Case Rep 2016,2:3(Suppl)